A Phase 2 interventional study of Ramucirumab and Merestinib in Biliary Tract Cancer, Metastatic Cancer and Advanced Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 82 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 155 studies in Biliary Tract Neoplasms with a site in United States — 48 open to participants now, 67 under way, 9 of them phase 3. Biliary Tract Neoplasms · United States.
Among the 155 studies in Biliary Tract Neoplasms with a site in United States, this one is the 25th largest by enrollment of the 140 interventional ones that give a count, is one of 6 that started in 2016, is one of 51 in phase 2, reaches primary completion later than 0 of the 66 other live ones, and was the 43rd registered.
521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.
Browse Biliary Tract Neoplasms studies →48 of the 155 studies in Biliary Tract Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Crescent Biopharma, Inc. · Sites in United States
Ages 18+
AbbVie · Sites in United States
Ages 18+
SK Life Science, Inc. · Sites in United States, Korea, Republic of
Ages 18+
InnoPharmax Inc. · Sites in United States, Taiwan
Ages 18+
J-Pharma Co., Ltd. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
155 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 64 · Phase 2 85 · Phase 3 14
First in 2002; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 309 is above the median of 58 across 429 interventional studies indexed under Biliary Tract Neoplasms.
Median enrollment 75 across the 140 interventional studies, 135 across the 14 observational. Of the 80 that completed or were terminated, 48 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
86 of 155 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Eli Lilly and Company has 4 studies filed under Biliary Tract Neoplasms — fewer than ten, so there is no comparison to draw.
20 of the studies in Biliary Tract Neoplasms with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05506943Phase 3Compass TherapeuticsA Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) | 2027-08-31 |
| NCT07265674Phase 3J-Pharma Co., Ltd.A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer | 2027-10 |
| NCT06219941AstraZenecaAZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | 2026-11-17 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
| NCT06451497Zumutor Biologics Inc.This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 155 studies in Biliary Tract Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 8 mg/kg ramucirumab plus 25 mg/square meter (mg/m²) cisplatin and 1000 mg/m² gemcitabine intravenously (IV) on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for ramucirumab therapy).
Drug: Ramucirumab · Drug: Cisplatin · Drug: Gemcitabine
Participants received placebo (indistinguishable and equivalent volume to ramucirumab) plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).
Drug: Cisplatin · Drug: Gemcitabine · Drug: Placebo IV
Participants received 80 mg merestinib orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days (1 cycle). Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for merestinib therapy).
Drug: Merestinib · Drug: Cisplatin · Drug: Gemcitabine
Participants received placebo (indistinguishable to merestinib) orally each day, plus 25 mg/m² cisplatin and 1000 mg/m² gemcitabine IV on Days 1 and 8, every 21 days. Participants may continue on study drug for up to 8 cycles (for cisplatin and gemcitabine therapy) or until disease progression, unacceptable toxicity, or other withdrawal criterion is met (for placebo therapy).
Drug: Cisplatin · Drug: Gemcitabine · Drug: Placebo Oral
Administered IV
Also known as: LY3009806
Administered orally
Also known as: LY2801653
Administered IV
Administered IV
Also known as: LY188011
Administered orally
Administered IV
Progression Free Survival (PFS)
PFS time was measured from the date of randomization until the first radiographic documentation of progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
Time frame: Randomization to Progressive Disease or Death from Any Cause (Up To 20 Months)
Overall Survival (OS)
OS defined as the time from from randomization to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.
Time frame: Randomization to Date of Death from Any Cause (Up To 48 Months)
Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR)
ORR was the number of participants who achieve a best overall response of CR or PR divided by the total number of participants randomized to the corresponding treatment arm as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Randomization to Disease Progression (Up To 30 Months)
Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR)
Disease Control Rate (DCR) was the number of participants who achieve a best overall response of CR, PR, or SD divided by the total number of participants randomized to the corresponding treatment arm as per RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Randomization to Disease Progression (Up To 30 Months)
Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab
PK was determined by the minimum observed plasma concentration (Cmin). 1 Cycle (C) = 21 days (D).
Time frame: C1 D8, C2 D1, C3 D1, C4 D1,C5 D1,C7 D1, C9 D1 and C13 D1: Within 3 days Prior to Infusion(PTI)
PK: Plasma Concentration of Merestinib
PK was presented through graphical overlay comparison versus historic data. No numerical summary of data was intended or produced.
Time frame: C1 D8; C2 D1; C4 D1; C6 D1; C8 D1; C2 D8; C4 D8; C6 D8; C8 D8: Morning
Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies
Number of participants with positive treatment emergent anti-ramucirumab antibodies (ADA) was summarized by treatment group.
Time frame: Predose Cycle 1 Day 1 through Follow Up (Up To 48 Months)
Change From Baseline in Functional Assessment of Cancer Therapy Hepatobiliary Questionnaire (FACT-Hep)
FACT-Hep consists of 45 items in five subscales (1) physical well-being (PWB) score rage 0 -28; (2) social well-being (SWB) score range 0-28; (3) emotional well-being (EWB) score range 0-24; (4) functional well-being (FWB) score range 0-28; and (5) the hepatobiliary cancer subscale (HCS) Score range 0-72. The Trial Outcomes Index (TOI) is the sum of the PWB, FWB and Hep subscales with a scores range of 0 to 128. The Total FACT-Hep score was the sum of all questions with a scores range of 0 to 180.Total FACT-G score was the sum of the 27 questions in the PWB, SFWB, EWB and FWB with a scores range of 0 to 108. The FACT-Hep Symptoms Index with 8 key questions and scores range of 0 to 32 from the Hep Subscale. Higher score in sub-score or total score indicates better QOL and better health state. Participants were classified as "Improved" if they had positive change from baseline, "Worsened" if they had negative change from baseline, and "Stable" otherwise.
Time frame: Baseline, Follow Up (Up To 48 Months)
Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score
EQ-5D-5L is a 2-part questionnaire that assesses general health status for 'today'. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using country-specific algorithms, with scores ranging from less than 0 (where zero is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). Index values were calculated using the US algorithm (-0.109 to 1). A higher score indicates better health state.
Time frame: Baseline, Follow Up (Up To 48 Months)
Change From Baseline in Participant-Reported EQ-5D-5L Visual Analog Scale (VAS) Score
EQ-5D-5L is a 2-part questionnaire that assesses general health status 'today'. The second part is assessed using a VAS on which the patient rates their perceived health state, ranging from 0 millimeter (the worst health you can imagine) to 100 millimeter (the best health you can imagine).
Time frame: Baseline, Follow Up (Up To 48 Months)
| Milestone | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine |
|---|---|---|---|---|
| Started | 106 | 52 | 102 | 49 |
| Received at least 1 dose of study drug | 104 | 52 | 102 | 48 |
| Completed | 100 | 47 | 92 | 45 |
| Not completed | 6 | 5 | 10 | 4 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 3 | 6 | 3 |
| Withdrew: On study treatment at study conclusion | 1 | 1 | 3 | 1 |
PFS time was measured from the date of randomization until the first radiographic documentation of progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
| Months | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Pooled Placebo |
|---|---|---|---|
| Progression Free Survival (PFS) | 6.47 (3.68 to 8.51) | 6.97 (4.34 to 9.79) | 6.64 (4.11 to 9.72) |
OS defined as the time from from randomization to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.
| Months | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Pooled Placebo |
|---|---|---|---|
| Overall Survival (OS) | 10.45 (8.48 to 11.76) | 14.03 (11.96 to 16.36) | 13.04 (11.40 to 15.31) |
ORR was the number of participants who achieve a best overall response of CR or PR divided by the total number of participants randomized to the corresponding treatment arm as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| Percentage of participants | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Pooled Placebo |
|---|---|---|---|
| Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR): Objective Response Rate (ORR) | 31.1 (22.3 to 39.9) | 19.6 (11.9 to 27.3) | 32.7 (23.5 to 41.8) |
Disease Control Rate (DCR) was the number of participants who achieve a best overall response of CR, PR, or SD divided by the total number of participants randomized to the corresponding treatment arm as per RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. SD was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| Percentage of participants | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Pooled Placebo |
|---|---|---|---|
| Percentage of Participants With a Best Overall Response of CR, PR, or Stable Disease (SD): Disease Control Rate (DCR) | 81.1 (73.7 to 88.6) | 83.3 (76.1 to 90.6) | 78.2 (70.2 to 86.3) |
PK was determined by the minimum observed plasma concentration (Cmin). 1 Cycle (C) = 21 days (D).
| Microgram per milliliter (µg/mL) | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine |
|---|---|
| Cycle 1 Day 8 (Week 1) | 46.2 ± 32 |
| Cycle 2 Day 1 (Week 3) | 38.1 ± 42 |
| Cycle 3 Day 1 (Week 6) | 54.1 ± 43 |
| Cycle 4 Day 1 (Week 9) | 77.3 ± 50 |
| Cycle 5 Day 1 (Week 12) | 82.9 ± 35 |
| Cycle 7 Day 1 (Week 18) | 85.6 ± 39 |
| Cycle 9 Day 1 (Week 24) | 82.7 ± 35 |
| Cycle 13 Day 1 (Week 36) | 97.7 ± 23 |
PK was presented through graphical overlay comparison versus historic data. No numerical summary of data was intended or produced.
No measurements were reported for this outcome.
Number of participants with positive treatment emergent anti-ramucirumab antibodies (ADA) was summarized by treatment group.
| Participants | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine |
|---|---|---|
| Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies | 3 | 0 |
FACT-Hep consists of 45 items in five subscales (1) physical well-being (PWB) score rage 0 -28; (2) social well-being (SWB) score range 0-28; (3) emotional well-being (EWB) score range 0-24; (4) functional well-being (FWB) score range 0-28; and (5) the hepatobiliary cancer subscale (HCS) Score range 0-72. The Trial Outcomes Index (TOI) is the sum of the PWB, FWB and Hep subscales with a scores range of 0 to 128. The Total FACT-Hep score was the sum of all questions with a scores range of 0 to 180.Total FACT-G score was the sum of the 27 questions in the PWB, SFWB, EWB and FWB with a scores range of 0 to 108. The FACT-Hep Symptoms Index with 8 key questions and scores range of 0 to 32 from the Hep Subscale. Higher score in sub-score or total score indicates better QOL and better health state. Participants were classified as "Improved" if they had positive change from baseline, "Worsened" if they had negative change from baseline, and "Stable" otherwise.
| Units on a Scale | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Pooled Placebo |
|---|---|---|---|
| PWB | -2.75 ± 0.43 | -2.88 ± 0.43 | -1.65 ± 0.42 |
| SWB | -0.26 ± 0.36 | 0.22 ± 0.36 | 0.56 ± 0.36 |
| EWB | 0.23 ± 0.31 | 0.64 ± 0.32 | 0.93 ± 0.31 |
| FWB | -2.40 ± 0.44 | -1.34 ± 0.44 | -0.75 ± 0.44 |
| HCS | -3.62 ± 0.63 | -2.32 ± 0.64 | -0.68 ± 0.63 |
| FACT-Hep | -1.11 ± 0.37 | -0.74 ± 0.37 | -0.09 ± 0.37 |
| TOI | -8.68 ± 1.31 | -6.43 ± 1.32 | -3.01 ± 1.30 |
EQ-5D-5L is a 2-part questionnaire that assesses general health status for 'today'. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using country-specific algorithms, with scores ranging from less than 0 (where zero is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). Index values were calculated using the US algorithm (-0.109 to 1). A higher score indicates better health state.
| Units on a Scale | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Pooled Placebo |
|---|---|---|---|
| Change From Baseline on the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Index Score | 0.61 ± 0.31 | 0.63 ± 0.29 | 0.66 ± 0.27 |
EQ-5D-5L is a 2-part questionnaire that assesses general health status 'today'. The second part is assessed using a VAS on which the patient rates their perceived health state, ranging from 0 millimeter (the worst health you can imagine) to 100 millimeter (the best health you can imagine).
| millimeter (mm) | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Pooled Placebo |
|---|---|---|---|
| Change From Baseline in Participant-Reported EQ-5D-5L Visual Analog Scale (VAS) Score | 66.44 ± 22.8 | 66.57 ± 21.73 | 69.08 ± 20.03 |
Collected over Randomization Up To 48 Months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 84/104 (80.8%) | 53/104 (51%) | 102/104 (98.1%) |
| Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 34/52 (65.4%) | 25/52 (48.1%) | 49/52 (94.2%) |
| 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 71/102 (69.6%) | 56/102 (54.9%) | 100/102 (98%) |
| Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 38/48 (79.2%) | 23/48 (47.9%) | 48/48 (100%) |
| Event | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine |
|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 6/104 | 3/52 | 2/102 | 3/48 |
| Atrial fibrillationCardiac disorders | 0/104 | 3/52 | 0/102 | 0/48 |
| NeutropeniaBlood and lymphatic system disorders | 3/104 | 1/52 | 5/102 | 0/48 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 3/104 | 0/52 | 5/102 | 1/48 |
| PyrexiaGeneral disorders | 5/104 | 1/52 | 4/102 | 2/48 |
| CholangitisHepatobiliary disorders | 5/104 | 0/52 | 2/102 | 1/48 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/104 | 2/52 | 1/102 | 2/48 |
| AscitesGastrointestinal disorders | 3/104 | 0/52 | 2/102 | 2/48 |
| Jaundice cholestaticHepatobiliary disorders | 1/104 | 0/52 | 0/102 | 2/48 |
| Acute kidney injuryRenal and urinary disorders | 2/104 | 0/52 | 3/102 | 2/48 |
| Event | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 63/104 | 24/52 | 52/102 | 19/48 |
| FatigueGeneral disorders | 61/104 | 17/52 | 53/102 | 22/48 |
| NauseaGastrointestinal disorders | 52/104 | 21/52 | 58/102 | 15/48 |
| ThrombocytopeniaBlood and lymphatic system disorders | 56/104 | 15/52 | 42/102 | 15/48 |
| AnemiaBlood and lymphatic system disorders | 52/104 | 22/52 | 40/102 | 24/48 |
| Abdominal painGastrointestinal disorders | 39/104 | 13/52 | 33/102 | 15/48 |
| Decreased appetiteMetabolism and nutrition disorders | 39/104 | 14/52 | 26/102 | 14/48 |
| ConstipationGastrointestinal disorders | 33/104 | 14/52 | 36/102 | 13/48 |
| VomitingGastrointestinal disorders | 34/104 | 12/52 | 34/102 | 12/48 |
| DiarrhoeaGastrointestinal disorders | 34/104 | 9/52 | 29/102 | 7/48 |
All randomized participants.
| Age, Continuous(years) | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Total |
|---|---|---|---|---|---|
| Mean | 63.49 ± 9.76 | 57.06 ± 11.67 | 60.95 ± 9.14 | 62.00 ± 9.14 | 61.33 ± 10.01 |
| Sex: Female, Male(Participants) | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Total |
|---|---|---|---|---|---|
| All randomized participants — Female | 60 | 26 | 54 | 22 | 162 |
| All randomized participants — Male | 46 | 26 | 48 | 27 | 147 |
| All randomized participants who received at least 1 dose of study drug — Female | 59 | 26 | 54 | 21 | 160 |
| All randomized participants who received at least 1 dose of study drug — Male | 45 | 26 | 48 | 27 | 146 |
| Ethnicity (NIH/OMB)(Participants) | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 106 | 52 | 102 | 49 | 309 |
| Race (NIH/OMB)(Participants) | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 20 | 11 | 26 | 9 | 66 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 1 | 1 | 4 |
| White | 78 | 35 | 70 | 38 | 221 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 5 | 4 | 1 | 17 |
| Region of Enrollment(Participants) | 8 mg/kg Ramucirumab + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo IV + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | 80 mg Merestinib + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Placebo Oral + 25 mg/m² Cisplatin + 1000 mg/m² Gemcitabine | Total |
|---|---|---|---|---|---|
| Argentina | 11 | 3 | 8 | 3 | 25 |
| Hungary | 5 | 7 | 4 | 1 | 17 |
| United States | 12 | 3 | 6 | 4 | 25 |
| Czechia | 2 | 2 | 5 | 2 | 11 |
| United Kingdom | 4 | 2 | 5 | 3 | 14 |
| Russia | 9 | 2 | 4 | 6 | 21 |
| Spain | 8 | 3 | 10 | 1 | 22 |
| Austria | 3 | 2 | 1 | 0 | 6 |
| South Korea | 8 | 6 | 12 | 4 | 30 |
| Sweden | 1 | 0 | 3 | 2 | 6 |
| Turkey | 6 | 7 | 7 | 3 | 23 |
| Belgium | 6 | 1 | 3 | 4 | 14 |
| Taiwan | 9 | 5 | 13 | 4 | 31 |
| Denmark | 1 | 1 | 3 | 1 | 6 |
| Mexico | 4 | 0 | 3 | 0 | 7 |
| Australia | 6 | 2 | 2 | 4 | 14 |
| France | 8 | 5 | 5 | 2 | 20 |
| Germany | 3 | 1 | 8 | 5 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and european union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2016 to primary completion in Feb 2018, 20 months.
Results were first posted in Feb 2021, 3 years after primary completion. A results delay was requested in Feb 2019.
Of 129 phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 68. This study's 20 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ramucirumab · Merestinib